6 pending office actions • 1 client
| Client (Assignee) | Pending OAs |
|---|---|
| Apellis Pharmaceuticals, Inc. | 6 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18573634 | COMPLEMENT INHIBITION | Apellis Pharmaceuticals, Inc. | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Dec 22, 2023 |
| 18563588 | GENOMIC EDITING OF COMPLEMENT | Apellis Pharmaceuticals, Inc. | HORTH, LISA ANNE | 1681 | Non-Final OA | Nov 22, 2023 |
| 18282664 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | Apellis Pharmaceuticals, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Sep 18, 2023 |
| 18266464 | GENOMIC EDITING OF COMPLEMENT | Apellis Pharmaceuticals, Inc. | HUMPHRIES, NICHOLAS ADAM | 1631 | Non-Final OA | Jun 09, 2023 |
| 18027331 | METHODS OF TREATING EYE DISORDERS | Apellis Pharmaceuticals, Inc. | SABILA, MERCY HELLEN | 1654 | Non-Final OA | Mar 20, 2023 |
| 17798339 | RNAS FOR COMPLEMENT INHIBITION | Apellis Pharmaceuticals, Inc. | HUDSON, AMY ROSE | 1636 | Final Rejection | Aug 09, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial